BCDA
Neutral signalScored 2026-08-03 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
BioCardia, Inc.
- Nom
- BioCardia, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $14.2M
- Employés
- 17
- PDG
- Peter A. Altman
- Site web
- https://www.biocardia.com
- Marché
- ACXPADILALZNAPREAPVOCELZ
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 131 900 titres (~124 066,00 $ US)
- Insiders
- Altman PeterSTERTZER SIMON H
- Total bought
-
$124,066
Avg buy (VWAP, 90d window) $0.91 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-07-29
- Last synced
-
2026-10-19 22:07:50
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-16 | Altman Peter | Buy · P | 300 | $0.95 | $285 | Form 4 |
| 2026-10-15 | Altman Peter | Buy · P | 200 | $0.95 | $190 | Form 4 |
| 2026-09-29 | Altman Peter | Buy · P | 1,000 | $1.03 | $1,030 | Form 4 |
| 2026-09-23 | Altman Peter | Buy · P | 1,900 | $1.05 | $1,995 | Form 4 |
| 2026-09-03 | Altman Peter | Buy · P | 800 | $1.09 | $872 | Form 4 |
| 2026-08-17 | Altman Peter | Buy · P | 5,400 | $0.93 | $5,022 | Form 4 |
| 2026-08-13 | Altman Peter | Buy · P | 1,900 | $0.92 | $1,748 | Form 4 |
| 2026-07-29 | Altman Peter | Buy · P | 5,000 | $0.78 | $3,900 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-03 Drivers: fundamentals. Moteurs : fondamentaux.
BCDA presents a critically fragile financial profile — zero revenue, persistent operating losses, and negative cash flows — that overwhelmingly undermines the moderate insider cluster buy signal (131,900 shares, ~$124K).
The first sentence of the analysis written for BCDA on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 1.12 · operating margin 0.0%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | -7463.8% | -1519.7% | -553.4% | 36.9% | |
| Ebit Margin | 0.0% | -13700.0% | -2425.8% | -880.3% | -1244.3% | |
| Ebitda Margin | 0.0% | -13584.5% | -2408.2% | -874.2% | -1238.4% | |
| Operating Profit Margin | 0.0% | -13794.8% | -2441.1% | -880.3% | -1244.3% | |
| Pretax Profit Margin | 0.0% | -13700.0% | -2425.8% | -880.7% | -1243.6% | |
| Continuous Operations Profit Margin | 0.0% | -13700.0% | -2425.8% | -880.7% | -1243.6% | |
| Net Profit Margin | 0.0% | -13700.0% | -2425.8% | -880.7% | -1243.4% | |
| Bottom Line Profit Margin | 0.0% | -13700.0% | -2425.8% | -880.7% | -1243.6% | |
| Current Ratio | 1.123 | 1.130 | 0.405 | 2.194 | 3.632 | |
| Quick Ratio | 1.123 | 1.130 | 0.405 | 2.194 | 3.632 | |
| Solvency Ratio | -3.067 | -2.729 | -2.503 | -2.413 | -2.351 | |
| Cash Ratio | 1.026 | 1.022 | 0.306 | 2.054 | 3.468 | |
| Price To Earnings Ratio | -1.016 | -0.752 | -1.216 | -9.358 | -7.802 | |
| Price To Earnings Growth Ratio | 0.018 | 0.012 | 0.066 | 0.919 | 0.157 | |
| Forward Price To Earnings Growth Ratio | 0.018 | 0.012 | 0.066 | 0.919 | 0.157 | |
| Price To Earnings Diluted Ratio | -1.016 | -0.752 | -1.216 | -9.358 | -7.802 | |
| Price To Earnings Diluted Growth Ratio | 0.018 | 0.012 | 0.066 | 0.919 | 0.157 | |
| Price To Book Ratio | 9.311 | 7.147 | -8.773 | 22.705 | 9.492 | |
| Price To Sales Ratio | 0.000 | 103.137 | 29.483 | 82.155 | 97.019 | |
| Price To Free Cash Flow Ratio | -1.120 | -0.745 | -1.408 | -10.448 | -9.395 | |
| Price To Operating Cash Flow Ratio | -1.121 | -0.745 | -1.410 | -10.517 | -9.500 | |
| Debt To Assets Ratio | 0.155 | 0.255 | 0.440 | 0.167 | 0.119 | |
| Debt To Equity Ratio | 0.590 | 1.136 | -0.820 | 0.333 | 0.180 | |
| Debt To Capital Ratio | 0.371 | 0.532 | -4.566 | 0.250 | 0.153 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 3.813 | 4.449 | -1.863 | 2.002 | 1.515 | |
| Working Capital Turnover Ratio | 0.000 | -0.063 | 0.447 | 0.192 | 0.072 | |
| Operating Cash Flow Ratio | -3.058 | -3.458 | -2.764 | -2.946 | -2.793 | |
| Operating Cash Flow Sales Ratio | 0.000 | -138.379 | -20.910 | -7.811 | -10.213 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | 1.001 | 1.001 | 1.007 | 1.011 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | -1,969.833 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -1,983.500 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -14.083 | -8.440 | -7.585 | -6.475 | -5.549 | |
| Capital Expenditure Coverage Ratio | -1,062.286 | -1,337.667 | -831.167 | -150.871 | -89.362 | |
| Dividend Paid And Capex Coverage Ratio | -1,062.286 | -1,337.667 | -831.167 | -150.871 | -89.362 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -0.824 | -0.579 | -1.243 | -8.913 | -6.959 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | ▲7463.8% | ▲1900.0% |
| Ebit Margin | 0.0% | ▲13700.0% | ▲3650.1% |
| Ebitda Margin | 0.0% | ▲13584.5% | ▲3621.1% |
| Operating Profit Margin | 0.0% | ▲13794.8% | ▲3672.1% |
| Pretax Profit Margin | 0.0% | ▲13700.0% | ▲3650.0% |
| Continuous Operations Profit Margin | 0.0% | ▲13700.0% | ▲3650.0% |
| Net Profit Margin | 0.0% | ▲13700.0% | ▲3650.0% |
| Bottom Line Profit Margin | 0.0% | ▲13700.0% | ▲3650.0% |
| Current Ratio | 1.123 | ▼-0.006 | ▼-0.573 |
| Quick Ratio | 1.123 | ▼-0.006 | ▼-0.573 |
| Solvency Ratio | -3.067 | ▼-0.338 | ▼-0.455 |
| Cash Ratio | 1.026 | ▲0.005 | ▼-0.549 |
| Price To Earnings Ratio | -1.016 | ▼-0.265 | ▲3.013 |
| Price To Earnings Growth Ratio | 0.018 | ▲0.006 | ▼-0.216 |
| Forward Price To Earnings Growth Ratio | 0.018 | ▲0.006 | ▼-0.216 |
| Price To Earnings Diluted Ratio | -1.016 | ▼-0.265 | ▲3.013 |
| Price To Earnings Diluted Growth Ratio | 0.018 | ▲0.006 | ▼-0.216 |
| Price To Book Ratio | 9.311 | ▲2.164 | ▲1.335 |
| Price To Sales Ratio | 0.000 | ▼-103.137 | ▼-62.359 |
| Price To Free Cash Flow Ratio | -1.120 | ▼-0.375 | ▲3.503 |
| Price To Operating Cash Flow Ratio | -1.121 | ▼-0.375 | ▲3.538 |
| Debt To Assets Ratio | 0.155 | ▼-0.101 | ▼-0.072 |
| Debt To Equity Ratio | 0.590 | ▼-0.546 | ▲0.306 |
| Debt To Capital Ratio | 0.371 | ▼-0.161 | ▲1.023 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 3.813 | ▼-0.636 | ▲1.830 |
| Working Capital Turnover Ratio | 0.000 | ▲0.063 | ▼-0.130 |
| Operating Cash Flow Ratio | -3.058 | ▲0.400 | ▼-0.054 |
| Operating Cash Flow Sales Ratio | 0.000 | ▲138.379 | ▲35.463 |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | ▲0.000 | ▼-0.003 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲393.967 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲396.700 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -14.083 | ▼-5.644 | ▼-5.657 |
| Capital Expenditure Coverage Ratio | -1062.286 | ▲275.381 | ▼-368.015 |
| Dividend Paid And Capex Coverage Ratio | -1062.286 | ▲275.381 | ▼-368.015 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -0.824 | ▼-0.245 | ▲2.879 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $8.3M | $6.0M | $14.1M | $111.1M | $98.5M | |
| Enterprise value | $6.4M | $4.6M | $14.3M | $105.3M | $87.5M | |
| EV / Sales | 0.00x | 78.65x | 29.93x | 77.92x | 86.18x | |
| EV / Op. cash flow | -0.86x | -0.57x | -1.43x | -9.97x | -8.44x | |
| EV / Free cash flow | -0.85x | -0.57x | -1.43x | -9.91x | -8.35x | |
| EV / EBITDA | -0.82x | -0.58x | -1.24x | -8.91x | -6.96x | |
| Net debt / EBITDA | 0.26x | 0.18x | -0.02x | 0.48x | 0.88x | |
| Current ratio | 1.12x | 1.13x | 0.41x | 2.19x | 3.63x | |
| Income quality | 0.90x | 1.01x | 0.86x | 0.89x | 0.82x | |
| Graham net-net | -$0 | -$0 | -$2 | $2 | $7 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.1% | 99.9% | |
| Working capital | $300K | $301K | -$2.1M | $4.3M | $9.8M | |
| Invested capital | $810K | $1.2M | -$791K | $6.0M | $11.8M | |
| Return on assets | -241.1% | -213.4% | -387.4% | -121.6% | -80.3% | |
| Operating ROA | -232.0% | -238.4% | -182.2% | -93.3% | -64.5% | |
| Return on tangible assets | -241.1% | -213.4% | -387.4% | -121.6% | -80.3% | |
| Return on equity | -919.3% | -949.3% | 721.8% | -243.4% | -121.6% | |
| Return on invested capital | -581.7% | -447.5% | 4057.1% | -182.5% | -103.2% | |
| Return on capital employed | -843.8% | -570.3% | 1875.0% | -191.7% | -105.2% | |
| Earnings yield | -98.7% | -132.8% | -82.3% | -10.7% | -12.8% | |
| Free cash flow yield | -89.3% | -134.3% | -71.0% | -9.6% | -10.6% | |
| Capex / Op. cash flow | -0.1% | -0.1% | -0.1% | -0.7% | -1.1% | |
| Capex / Depreciation | 1.4% | 9.0% | 14.3% | 85.4% | 193.3% | |
| Capex / Sales | 0.0% | 10.3% | 2.5% | 5.2% | 11.4% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 501.2% | |
| R&D / Sales | 0.0% | 7563.8% | 1619.7% | 653.4% | 843.2% | |
| Stock comp / Sales | 0.0% | 1277.6% | 215.9% | 87.5% | 163.6% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 48d | 54d | 53d | |
| Days payables outstanding | 463d | 32d | 42d | 28d | 289d | |
| Operating cycle | 0d | 0d | 48d | 54d | 53d | |
| Cash conversion cycle | -463d | -32d | 6d | 26d | -236d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-19 BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter SUNNYVALE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted its pre-submission package for marketing clearance of its Helix catheter (“Helix”) intended for therapeutic and diagnostic agent delivery.
- 2026-10-07 BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting SUNNYVALE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the upcoming presentation of a scientific poster entitled “Cardiac Delivery of Autologous Minimally Processed Cell Therapy in HFrEF: Multicenter, Double Blind RCT (CardiAMP HF II)” at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoenix, AZ from October 9 – 12, 2026.
- 2026-10-01 BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter SUNNYVALE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its revised Pre-Submission to FDA Center for Devices and Radiological Health (CDRH) under its Q-Submission program for the approval of its Helix Catheter (“Helix”) for therapeutic and diagnostic agent delivery to the heart.
- 2026-09-23 BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission SUNNYVALE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update on near term milestones.
- 2026-09-10 BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference SUNNYVALE, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Peter Altman, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 14-16, 2026.
- 2026-08-24 BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval SUNNYVALE, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces receipt of FDA confirmation of the outcome of its Pre-Submission Meeting on the Helix Transendocardial Delivery Catheter System (Helix).
- 2026-08-13 BioCardia, Inc. (BCDA) Q2 2026 Earnings Call Transcript BioCardia, Inc. (BCDA) Q2 2026 Earnings Call Transcript
- 2026-08-05 BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026 SUNNYVALE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the second quarter of 2026 by conference call on Wednesday, August 12, 2026 at 4:30 PM EDT. Following management''s formal remarks, there will be a question-and-answer session.
- 2026-07-28 New Strong Sell Stocks for July 28th LUNR, GLDG and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 28, 2026.